Neuroprotection in brain and spinal cord trauma

Eugene Fu, Ramachandra P. Tummala

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose of review: Traumatic brain and spinal cord injuries continue to be a public health problem. These types of injuries often occur in early adulthood and have a major impact for society. This review discusses strategies and therapeutic agents for perioperative neuroprotection in the management of brain and spinal cord trauma. Recent findings: There are no definitive drugs or strategies that can be utilized to provide perioperative neuroprotection in brain and spinal cord trauma patients. Phase III trials of several pharmacologic agents, including inhibitors of oxidative and excitotoxic injury, have been unable to demonstrate clinical efficacy. Although experimental animal data for hypothermia have been promising over the years, clinical application of therapeutic hypothermia cannot be recommended for routine use in neurotrauma patients. Administration of methylprednisolone, which has become common practice in acute spinal cord injury, has come under close scrutiny. Various experimental animal investigations suggest that potential therapeutic agents include estrogen, progesterone, minocycline, erythropoietin, and magnesium. Summary: The main priority in the initial treatment of brain and spinal cord trauma is to maintain oxygenation and perfusion in order to avoid aggravating secondary injury. Future progress will depend on the translation of neuroprotective strategies into well designed clinical trials with promising outcomes.

Original languageEnglish
Pages (from-to)181-187
Number of pages7
JournalCurrent Opinion in Anaesthesiology
Volume18
Issue number2
StatePublished - Apr 1 2005

Fingerprint

Spinal Cord Injuries
Brain
Wounds and Injuries
Induced Hypothermia
Minocycline
Methylprednisolone
Erythropoietin
Hypothermia
Magnesium
Progesterone
Estrogens
Therapeutics
Public Health
Perfusion
Neuroprotection
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Neuroprotection
  • Neurotrauma
  • Spinal cord injury
  • Traumatic brain injury

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Neuroprotection in brain and spinal cord trauma. / Fu, Eugene; Tummala, Ramachandra P.

In: Current Opinion in Anaesthesiology, Vol. 18, No. 2, 01.04.2005, p. 181-187.

Research output: Contribution to journalArticle

Fu, Eugene ; Tummala, Ramachandra P. / Neuroprotection in brain and spinal cord trauma. In: Current Opinion in Anaesthesiology. 2005 ; Vol. 18, No. 2. pp. 181-187.
@article{3287e2ee24684c92b1827b065c366c12,
title = "Neuroprotection in brain and spinal cord trauma",
abstract = "Purpose of review: Traumatic brain and spinal cord injuries continue to be a public health problem. These types of injuries often occur in early adulthood and have a major impact for society. This review discusses strategies and therapeutic agents for perioperative neuroprotection in the management of brain and spinal cord trauma. Recent findings: There are no definitive drugs or strategies that can be utilized to provide perioperative neuroprotection in brain and spinal cord trauma patients. Phase III trials of several pharmacologic agents, including inhibitors of oxidative and excitotoxic injury, have been unable to demonstrate clinical efficacy. Although experimental animal data for hypothermia have been promising over the years, clinical application of therapeutic hypothermia cannot be recommended for routine use in neurotrauma patients. Administration of methylprednisolone, which has become common practice in acute spinal cord injury, has come under close scrutiny. Various experimental animal investigations suggest that potential therapeutic agents include estrogen, progesterone, minocycline, erythropoietin, and magnesium. Summary: The main priority in the initial treatment of brain and spinal cord trauma is to maintain oxygenation and perfusion in order to avoid aggravating secondary injury. Future progress will depend on the translation of neuroprotective strategies into well designed clinical trials with promising outcomes.",
keywords = "Neuroprotection, Neurotrauma, Spinal cord injury, Traumatic brain injury",
author = "Eugene Fu and Tummala, {Ramachandra P.}",
year = "2005",
month = "4",
day = "1",
language = "English",
volume = "18",
pages = "181--187",
journal = "Current Opinion in Anaesthesiology",
issn = "0952-7907",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Neuroprotection in brain and spinal cord trauma

AU - Fu, Eugene

AU - Tummala, Ramachandra P.

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Purpose of review: Traumatic brain and spinal cord injuries continue to be a public health problem. These types of injuries often occur in early adulthood and have a major impact for society. This review discusses strategies and therapeutic agents for perioperative neuroprotection in the management of brain and spinal cord trauma. Recent findings: There are no definitive drugs or strategies that can be utilized to provide perioperative neuroprotection in brain and spinal cord trauma patients. Phase III trials of several pharmacologic agents, including inhibitors of oxidative and excitotoxic injury, have been unable to demonstrate clinical efficacy. Although experimental animal data for hypothermia have been promising over the years, clinical application of therapeutic hypothermia cannot be recommended for routine use in neurotrauma patients. Administration of methylprednisolone, which has become common practice in acute spinal cord injury, has come under close scrutiny. Various experimental animal investigations suggest that potential therapeutic agents include estrogen, progesterone, minocycline, erythropoietin, and magnesium. Summary: The main priority in the initial treatment of brain and spinal cord trauma is to maintain oxygenation and perfusion in order to avoid aggravating secondary injury. Future progress will depend on the translation of neuroprotective strategies into well designed clinical trials with promising outcomes.

AB - Purpose of review: Traumatic brain and spinal cord injuries continue to be a public health problem. These types of injuries often occur in early adulthood and have a major impact for society. This review discusses strategies and therapeutic agents for perioperative neuroprotection in the management of brain and spinal cord trauma. Recent findings: There are no definitive drugs or strategies that can be utilized to provide perioperative neuroprotection in brain and spinal cord trauma patients. Phase III trials of several pharmacologic agents, including inhibitors of oxidative and excitotoxic injury, have been unable to demonstrate clinical efficacy. Although experimental animal data for hypothermia have been promising over the years, clinical application of therapeutic hypothermia cannot be recommended for routine use in neurotrauma patients. Administration of methylprednisolone, which has become common practice in acute spinal cord injury, has come under close scrutiny. Various experimental animal investigations suggest that potential therapeutic agents include estrogen, progesterone, minocycline, erythropoietin, and magnesium. Summary: The main priority in the initial treatment of brain and spinal cord trauma is to maintain oxygenation and perfusion in order to avoid aggravating secondary injury. Future progress will depend on the translation of neuroprotective strategies into well designed clinical trials with promising outcomes.

KW - Neuroprotection

KW - Neurotrauma

KW - Spinal cord injury

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=17144422879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144422879&partnerID=8YFLogxK

M3 - Article

C2 - 16534336

AN - SCOPUS:17144422879

VL - 18

SP - 181

EP - 187

JO - Current Opinion in Anaesthesiology

JF - Current Opinion in Anaesthesiology

SN - 0952-7907

IS - 2

ER -